News|Articles|January 28, 2026
Striking a Balance Between Speed and Quality to Deliver Next-Generation Therapeutics
Author(s)Fujifilm
Discover how a robust platform enables fast, high-quality bispecific antibody production by optimizing gene ratios, CLD, and analytics for purity and yield.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
HanchorBio–WuXi Biologics Partnership Targets Fusion Protein Development Challenges
2
GSK’s Arexvy Gains EU Approval for Adults Aged 18 Years and Older
3
FDA Fast Tracks Innovent’s Trispecific Antibody for Multiple Myeloma
4
Subvisible Particulate Matter Testing
5